Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Drug: Cetuximab + Gefitinib

First Posted Date: 2005-09-13

Last Posted Date: 2015-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT00162318

Locations: 🇺🇸
Local Institution, Pittsburgh, Pennsylvania, United States

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

Phase 2

Completed

Conditions: Mucinous Gastrointestinal Adenocarcinoma

Interventions: Drug: cetuximab

First Posted Date: 2005-09-13

Last Posted Date: 2015-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT00162110

Locations: 🇺🇸
Local Institution, Cincinnati, Ohio, United States

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

Phase 3

Completed

Conditions: Diabetes Mellitus
Asthma
Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Human Insulin Inhalation Powder
Drug: injected insulin

First Posted Date: 2005-09-12

Last Posted Date: 2019-09-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 299

Registration Number: NCT00157339

Locations: 🇹🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangkok, Thailand

Tadalafil in Subjects With Mild to Moderate Hypertension

Phase 2

Completed

Conditions: Hypertension

First Posted Date: 2005-09-12

Last Posted Date: 2007-10-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 180

Registration Number: NCT00157326

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bothell, Washington, United States

Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: pemetrexed
Drug: cyclophosphamide
Drug: doxorubicin
Drug: docetaxel

First Posted Date: 2005-09-08

Last Posted Date: 2012-03-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 257

Registration Number: NCT00149214

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

A Study in People With High Cholesterol

Phase 2

Completed

Conditions: Hypercholesterolemia

First Posted Date: 2005-08-23

Last Posted Date: 2007-04-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 300

Registration Number: NCT00133380

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingsport, Tennessee, United States

Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: placebo
Drug: haloperidol
Drug: olanzapine

First Posted Date: 2005-08-11

Last Posted Date: 2010-12-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 224

Registration Number: NCT00129220

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Human Insulin Inhalation Powder
Drug: Injectable Insulin
Drug: Insulin Glargine

First Posted Date: 2005-08-08

Last Posted Date: 2018-03-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 385

Registration Number: NCT00127634

Locations: 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Noida, India
🇭🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Szeged, Hungary

A Study of Duloxetine in the Treatment of Fibromyalgia

Phase 3

Completed

Conditions: Fibromyalgia

First Posted Date: 2005-08-02

Last Posted Date: 2007-05-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 320

Registration Number: NCT00125892

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours , EST ) or speak with your personal physician, Taipei, Taiwan
🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Morelia, Michoacan, Mexico
🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your person physician, Taichung, Taiwan

and more 7 locations

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

Phase 3

Completed

Conditions: Pulmonary Hypertension

Interventions: Drug: placebo
Drug: tadalafil

First Posted Date: 2005-08-02

Last Posted Date: 2008-02-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 406

Registration Number: NCT00125918

Locations: 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bergamo, Italy

Home Terms & Conditions Privacy Policy